Skip to main content

Advertisement

SpringerLink
Log in

Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Gait imbalance is one of the frequent complications in subjects with multiple sclerosis (MS). Fampridine (4-aminopyridine) is a potassium-channel blocker that is administered for gait imbalance in MS. Different studies showed the effects of fampridine on gait status based on various tests in subjects with MS. Some showed significant improvement after treatment, and others did not. So, we designed this systematic review, and meta-analysis to estimate the pooled effects of fampridine on gait status in patients with MS.

Methods

The main goal is the evaluation of times of different gait test pre and post fampridine treatment. Two independent expert researchers conducted a systematic and comprehensive search in PubMed, Scopus, EMBASE, Web of Science, and Google Scholar and also gray literature, including references of the references and conference abstracts. The search was done on September 16, 2022. Before-after studies trials reporting scores of the walking tests.

We extracted data regarding the total number of participants, first author, publication year, country of origin, mean age, Expanded Disability Status Scale (EDSS), and the results of walking tests.

Results

The literature search revealed 1963 studies; after deleting duplicates, 1098 studies remained. Seventy-seven full texts were evaluated. Finally, 18 studies were included for meta-analysis, while most of them were not placebo-controlled trials. The most frequent country of origin was Germany, and the mean age and EDSS ranged between 44 and 56 years and 4 and 6, respectively. The studies were published between 2013 and 2019. The pooled standardized mean difference (SMD) (after-before) of the MS Walking Scale (MSWS-12) was – 1.97 (95%CI: – 1.7, – 1.03) (I2 = 93.1%, P < 0.001). The pooled SMD (after-before) of the six-minute walk test (6MWT) was 0.49 (95%CI: 0.22, – 0.76) (I2 = 0%, P = 0.7). The pooled SMD (after-before) of T Timed 25-Foot Walk (T25FW) was – 0.99(95%CI: – 1.52, – 0.47) (I2 = 97.5%, P < 0.001).

Conclusion

This systematic review and meta-analysis show that fampridine improves gait imbalance in patients with MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M (2014) Relationship between sleep quality and quality of life in patients with multiple sclerosis. Int J Prev Med 5(12):1582

    PubMed  PubMed Central  Google Scholar 

  2. Cameron MH, Wagner JM (2011) Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep 11(5):507–515

    Article  CAS  PubMed  Google Scholar 

  3. Cohen JA, Rudick RA (2007) Aspects of multiple sclerosis that relate to trial design and clinical management. Multiple Sclerosis Therapeutics 3:22

    Google Scholar 

  4. Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(3):606–616

    Article  PubMed  Google Scholar 

  5. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. The Lancet 373(9665):732–738

    Article  CAS  Google Scholar 

  6. Dunn J, Blight A (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27(7):1415–1423

    Article  CAS  PubMed  Google Scholar 

  7. Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A (2016) Effect of fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with multiple sclerosis. J Neurol Sci 360:102–109

    Article  CAS  PubMed  Google Scholar 

  8. Broicher SD, Filli L, Geisseler O, Germann N, Zörner B, Brugger P et al (2018) Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol 265(5):1016–1025

    Article  CAS  PubMed  Google Scholar 

  9. Henkens MT, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, BarandiaránAizpurua A, Verdonschot JA et al (2020) Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction A systematic review. Eur J Heart Failure 22(9):1586–1597

    Article  Google Scholar 

  10. Lundh A, Gøtzsche PC (2008) Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 8(1):1–9

    Article  Google Scholar 

  11. Mejuto B, Castellano P, Castro C, López LM (2017) Assessment of the efficacy and safety of fampridine. Farm Hosp 41(2):283–291

    PubMed  Google Scholar 

  12. Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager E (2014) Changes in cognition, arm function and lower body function after slow-release Fampridine treatment. Mult Scler J 20(14):1872–1880

    Article  CAS  Google Scholar 

  13. Costa-Arpín E, Pato A, Rodríguez-Regal A, Midaglia L, Yáñez R, Muñoz D et al (2016) Clinical response and tolerability of fampridine in clinical practice. Neurodegenerative Dis Manag 6(2):99–105

    Article  Google Scholar 

  14. Ahdab R, Shatila MM, Shatila AR, Khazen G, Freiha J, Salem M et al (2019) Cortical excitability measures may predict clinical response to fampridine in patients with multiple sclerosis and gait impairment. Brain Sci 9(12):357

    Article  PubMed Central  Google Scholar 

  15. Korsen M, Kunz R, Schminke U, Runge U, Kohlmann T, Dressel A (2017) Dalfampridine effects on cognition, fatigue, and dexterity. Brain and behavior 7(1):e00559

    Article  PubMed  Google Scholar 

  16. Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R (2014) Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Mult Scler J 20(6):733–738

    Article  CAS  Google Scholar 

  17. Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U et al (2015) Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol 15(1):1–8

    Article  Google Scholar 

  18. Brambilla L, Sebastiano DR, Aquino D, Clerici VT, Brenna G, Moscatelli M et al (2016) Early effect of dalfampridine in patients with MS: a multi-instrumental approach to better investigate responsiveness. J Neurol Sci 368:402–407

    Article  CAS  PubMed  Google Scholar 

  19. Jensen H, Nielsen J, Ravnborg M, Dalgas U, Aagaard P, Stenager E (2016) Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients A randomized, double blind, placebo controlled study. Multiple Sclerosis and Related Disorders 10:137–144

    Article  CAS  PubMed  Google Scholar 

  20. Stellmann J-P, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C (2016) Fampridine and real-life walking in multiple sclerosis: low predictive value of clinical test for habitual short-term changes. J Neurol Sci 368:318–325

    Article  CAS  PubMed  Google Scholar 

  21. Pickering H, Murray J, Lin CS-Y, Cormack C, Martin A, Kiernan MC et al (2017) Fampridine treatment and walking distance in multiple sclerosis: a randomised controlled trial. Clin Neurophysiol 128(1):93–99

    Article  PubMed  Google Scholar 

  22. Macdonell R, Nagels G, Laplaud D-A, Pozzilli C, de Jong B, Martins da Silva A et al (2016) Improved patient-reported health impact of multiple sclerosis: the ENABLE study of PR-fampridine. Multiple Sclerosis J 22(7):944–954

    Article  CAS  Google Scholar 

  23. Ruck T, Bittner S, Simon O, Göbel K, Wiendl H, Schilling M et al (2014) Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci 337(1–2):18–24

    Article  CAS  PubMed  Google Scholar 

  24. Crayton H, Sidovar M, Wulf S, Guo A (2015) Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program. The Patient-Patient-Centered Outcomes Res 8(3):283–291

    Article  Google Scholar 

  25. van Munster C, Kaya L, Lam K, Kalkers N, Killestein J, Uitdehaag B (2020) Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making. Multiple Sclerosis and Related Disorders 38:101489

    Article  PubMed  Google Scholar 

  26. Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Barreira AA, Brooks JBB et al (2016) Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders. NeuroRehabilitation 39(2):301–304

    Article  PubMed  Google Scholar 

  27. Rabadi MH, Kreymborg K, Vincent AS (2013) Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function. Drugs R&D 13(3):175–181

    Article  CAS  Google Scholar 

  28. Behm K, Morgan P (2018) The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disabil Rehabil 40(15):1733–1744

    Article  PubMed  Google Scholar 

  29. Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S et al (2019) Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 33(11):1087–1099

    Article  CAS  PubMed  Google Scholar 

  30. Brown TR, Simnad VI (2016) A randomized crossover trial of dalfampridine extended release for effect on ambulatory activity in people with multiple sclerosis. Int J MS care 18(4):170–176

    Article  PubMed  PubMed Central  Google Scholar 

  31. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4):494–502

    Article  CAS  PubMed  Google Scholar 

  32. Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K et al (2020) Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler J 26(1):91–98

    Article  Google Scholar 

  33. Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111(1):224–259

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran

    Sahar Ghorbanpour, Sarvenaz Rahimibarghani & Setareh Rohani

  2. Student’s Scientific Research Center, Tehran University of Medical Sciences, Tehran, Mahsa Ghajarzadeh, Iran

    Mohsen Rastkar

  3. Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

    Mahsa Ghajarzadeh

  4. Multiple Sclerosis Research Group (MSRG), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

    Mahsa Ghajarzadeh

Authors
  1. Sahar Ghorbanpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarvenaz Rahimibarghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Setareh Rohani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohsen Rastkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahsa Ghajarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahsa Ghajarzadeh.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval

None.

Informed consent

Not applicable.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghorbanpour, S., Rahimibarghani, S., Rohani, S. et al. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci 44, 3059–3069 (2023). https://doi.org/10.1007/s10072-023-06795-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-023-06795-9

Keywords

Search

Navigation